Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001562721 | SCV001785531 | uncertain significance | not provided | 2023-06-09 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001562721 | SCV002331658 | likely benign | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002573178 | SCV003700101 | uncertain significance | Inborn genetic diseases | 2022-10-04 | criteria provided, single submitter | clinical testing | The c.6731C>T (p.T2244M) alteration is located in exon 5 (coding exon 5) of the FAT4 gene. This alteration results from a C to T substitution at nucleotide position 6731, causing the threonine (T) at amino acid position 2244 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038263 | SCV005662357 | uncertain significance | Van Maldergem syndrome 2; Hennekam lymphangiectasia-lymphedema syndrome 2 | 2024-05-15 | criteria provided, single submitter | clinical testing |